- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis in America Medical Cannabis Access for Pain Treatment
- Join Join
Oklahoma Medical Cannabis Laws & Regulations
In April 2015, Gov. Fallin signed HB 2154, Katie and Cayman's Law.
Katie and Cayman’s Law allows physicians in Oklahoma to recommend a clinical trial with cannabis oil containing high concentrations of CBD (one of the compounds founds in cannabis) to minors (18 years and under) suffering from a severe epilepsy disorder (e.g. Lennox-Gastaut Syndrome or Dravet Syndrome). The CBD oil for the trial must be obtained from a provider approved by the U.S. Food and Drug Administration (“FDA”) who has manufactured and tested the oil in a facility approved by the FDA.
The law also exempts minors and their guardians or caretakers from criminal prosecution for possession of CBD oil if they have received a written certification from a physician licensed in Oklahoma that the person suffers from a severe form of epilepsy that is not adequately treated by traditional medical therapies.
In each case, the CBD oil may not contain more than 0.3% THC.
In May 2016, Gov. Fallin signed HB 2835, which expanded the law to apply to all persons (as opposed to just minors). This bill also extended legal protection for possession of CBD oil to include patients suffering from spasticity due to multiple sclerosis or paraplegia, intractable nausea and vomiting or appetite stimulation with chronic wasting diseases.
Neither bill created a framework for the production, distribution or analysis of the CBD oil. Presumably patients are supposed to illegally bring CBD oil in from another state or to participate in clinical trials conducted at Oklahoma universities.
HB 2835 (2016) - expansion of protections